NR ANES
AU Head,M.W.; Farquhar,C.F.; Mabbott,N.A.; Fraser,J.R.
TI The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention.
QU Expert Opinion on Therapeutic Targets 2001 Oct; 5(5): 569-585
PT journal article
AB Primary neurodegenerative diseases tend to be intractable and largely affect the elderly. There is rarely the opportunity to identify individuals at risk and the appearance of clinical symptoms usually signifies the occurrence of irreversible neurological damage. This situation describes sporadic Creutzfeldt-Jakob disease which occurs world-wide, affecting one person per million per annum. The epidemic of bovine spongiform encephalopathy in the UK in the 1980s and the subsequent causal appearance of variant Creutzfeldt-Jakob disease in young UK residents in the 1990s has refocused attention on this whole group of diseases, known as the transmissible spongiform encephalopathies or prion diseases. The potentially lengthy incubation period of variant Creutzfeldt-Jakob disease, including perhaps an obligate peripheral phase, prior to neuroinvasion, marks variant Creutzfeldt-Jakob disease out as different from sporadic Creutzfeldt-Jakob disease. The formal possibility of detecting individuals infected with the bovine spongiform encephalopathy agent during this asymptomatic peripheral phase provides a strong incentive for the development of therapies for transmissible spongiform encephalopathies. This review focuses on recent advances in the understanding of the pathogenesis of these diseases, with particular reference to in vitro and animal model systems. Such systems have proved invaluable in the identification of potential therapeutic strategies that either specifically target the prion protein or more generally target peripheral pathogenesis. Furthermore, recent experiments in animal models suggest that even after neuroinvasion there may be pharmacological avenues to explore that might retard or even halt the degenerative process.
AD Mark W. Head (m.w.head@ed.ac.uk), National CJD Surveillance Unit and Department of Pathology, Bryan Matthews Building, Western General Hospital, University of Edinburgh, Edinburgh, Scotland, UK; Christine F. Farquhar (christine.farquhar@bbsrc.ac.uk), Neil A. Mabbott (neil.mabbott@bbsrc.ac.uk), Janet R. Fraser (janet.fraser@bbsrc.ac.uk), Institute for Animal Health, BBSRC and MRC, Neuropathogenesis Unit, Ogston Building, West Mains Road, Edinburgh EH9 3JF, Scotland, UK
SP englisch